Cancer diagnostics technology developer Inivata has secured $25m from NeoGenomics to take its total funding to more than $128m.
Cancer diagnostics service provider NeoGenomics invested $25m in UK-based liquid cancer biopsy developer Inivata yesterday through a strategic partnership deal.
Inivata is developing liquid biopsy tests under the InVision brand in order to diagnose cancer through the detection of genomic markers that are indicative of circulating tumour DNA.
The company’s flagship product, InVisionFirst-Lung, tests patients for advanced non-small cell lung cancer, a subtype responsible for an estimated 80% to 85% of all lung cancers. NeoGenomics will offer the product to…
